Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study

Journal of Clinical Oncology

Volumn 27, Issue 27, 2009, Pages 4522-4529

  Sparano, Joseph A ^a   Makhson, Anatoly N ^a   Semiglazov, Vladimir F ^a   Tjulandin, Sergei A ^a   Balashova, Olga I ^a   Bondarenko, Igor N ^a   Bogdanova, Natalia V ^a   Manikhas, George M ^a   Oliynychenko, Gennadiy P ^a   Chatikhine, Valery A ^a   Zhuang, Sen H ^a   Xiu, Liang ^a   Yuan, Zhilong ^a   Rackoff, Wayne R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HEART DISEASES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; POLYETHYLENE GLYCOLS; TAXOIDS; TIME FACTORS;

EID: 76749156249     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.5013     Document Type: Article

References (31)

1. Hortobagyi GN: Chemotherapy of breast cancer: A historical perspective. Semin Oncol 24:S17-1-S17-4, 1997
2. Bontenbal M, Creemers GJ, Braun HJ, et al: Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 23:7081-7088, 2005
3. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
4. Bergh J, Jonsson PE, Glimelius B, et al: A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 40:253-281, 2001
5. Bria E, Giannarelli D, Felici A, et al: Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. Cancer 103:672-679, 2005
6. Lord S, Ghersi D, Gattellari M, et al: Antitumour antibiotic containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 4:CD003367, 2004
7. Verma S, Dent S, Chow BJ, et al: Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev 34:391-406, 2008
8. Jensen BV: Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 33:S15-21, 2006
9. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
10. Hilger RA, Richly H, Grubert M, et al: Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil. Int J Clin Pharmacol Ther 43:588-589, 2005
11. O'Brien ME, Wigler N, Inbar M, et al: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440-449, 2004
12. Sparano JA, Winer EP: Liposomal anthracyclines for breast cancer. Semin Oncol 28:32-40, 2001
13. Safra T, Muggia F, Jeffers S, et al: Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11: 1029-1033, 2000
14. Trudeau ME, Eisenhauer EA, Higgins BP, et al: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 14:422-428, 1996
15. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354, 1999
16. Sparano JA, Malik U, Rajdev L, et al: Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 19:3117-3125, 2001
17. Alexopoulos A, Karamouzis MV, Stavrinides H, et al: Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol 15: 891-895, 2004
18. Woff AC, Wang A, Sparano JA, et al: Cardiac safety and clinical activity of pegylated liposomal doxorubicin (D) and docetaxel (T) with and without trastuzumab (H) as 1(st) line chemotherapy in HER2-positive and HER2-negative metastatic breast cancer (MBC): Eastern Cooperative Oncology Group (ECOG) trial E3198. Breast Cancer Res Treat 88: S125, 2004 (abstr 3040), 2004
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
20. Brady MJ, Cella DF, Mo F, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 15:974-986, 1997
21. Miles D, Chan A, Romieu G, et al: Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26:43s, 2008 (suppl; abstr LBA1011)
22. Albain KS, Nag SM, Calderillo-Ruiz G, et al: Gemcitabine plus Paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26: 3950-3957, 2008
23. Carlson RW, Brown E, Burstein HJ, et al: NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 4:S1-26, 2006 (suppl 1)
24. Keller AM, Mennel RG, Georgoulias VA, et al: Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22:3893-3901, 2004
25. Alba E, Ruiz-Borrego M, Martin M, et al: Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study. J Clin Oncol 25:18s, 2007 (suppl; abstr 1007)
26. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002
27. Thomas ES, Gomez HL, Li RK, et al: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217, 2007
28. Lyseng-Williamson KA, Fenton C: Docetaxel: A review of its use in metastatic breast cancer. Drugs 65:2513-2531, 2005
29. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebocontrolled phase III study. J Clin Oncol 23:1178-1184, 2005
30. Harvey V, Mouridsen H, Semiglazov V, et al: Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24:4963-4970, 2006
31. Sledge GW, Neuberg D, Bernardo P, et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 21:588-592, 2003